Maxim Group set a $2.00 target price on Cytori Therapeutics (NASDAQ:CYTX) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. Laidlaw reaffirmed a buy rating and issued a $1.65 target price on shares of Cytori Therapeutics in a research report on Thursday, February 22nd. B. Riley raised Cytori Therapeutics from a neutral rating to a buy rating in a research report on Friday, March 9th. HC Wainwright initiated coverage on Cytori Therapeutics in a research report on Monday, May 7th. They issued a buy rating and a $4.00 target price for the company. Zacks Investment Research raised Cytori Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday. Finally, ValuEngine raised Cytori Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $2.24.
Cytori Therapeutics traded down $0.04, hitting $0.28, during midday trading on Friday, MarketBeat.com reports. The stock had a trading volume of 781,836 shares, compared to its average volume of 414,635. The stock has a market cap of $18.42 million, a P/E ratio of -0.42 and a beta of 3.10. Cytori Therapeutics has a 52 week low of $0.27 and a 52 week high of $0.29.
Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $2.43 million. Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 418.36%. During the same period last year, the business earned ($0.24) earnings per share. research analysts anticipate that Cytori Therapeutics will post -0.12 EPS for the current fiscal year.
In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 286,982 shares of Cytori Therapeutics stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $0.31, for a total transaction of $88,964.42. Following the completion of the transaction, the insider now directly owns 5,118,627 shares of the company’s stock, valued at $1,586,774.37. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its stake in shares of Cytori Therapeutics (NASDAQ:CYTX) by 134.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,136,041 shares of the biotechnology company’s stock after acquiring an additional 1,223,046 shares during the quarter. Perkins Capital Management Inc. owned approximately 6.08% of Cytori Therapeutics worth $644,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.92% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.